Di Trapani G, Mei D, Marra C, Mazza S, Capuano A
Institute of Neurology, Catholic University, Rome, Italy.
Clin Ter. 2000 May-Jun;151(3):145-8.
Gabapentin is an antiepileptic drug of new generation that increases brain GABA levels. We report the results of a three-month randomised double-blind placebo-controlled study on the effects of gabapentin in the prophylaxis of patients with migraine meeting the IHS criteria.
We treated 63 patients suffering from migraine with or without aura. Patients treated their attack at home using symptomatic drugs and clinical assessment was recorded on a diary. After a washout of 8 week from any other prophylactic treatment, all patients were treated with 1200 mg/day of gabapentin; this is our therapeutic plan: 400 mg/day from 1st to 3rd day, 800 mg/day from 4th to 6th day and 1200 mg/day from 7th day.
No patients withdrew, gabapentin was well tolerated; adverse events (somnolence, dizziness, tremor, fatigue and ataxia) generally were transient and mild to moderate in severity and in 13 patients (27%) only occurred. At the end of treatment, in such case, we reported a significative reduction of frequency and intensity of migraine in 30 patients treated with gabapentin.
Our observations indicate that gabapentin is well tolerated by patients and that reduces headache frequency and use of symptomatic drugs in both groups. Gabapentin shows to have an effective therapeutic action in the prophylactic treatment of migraine.
加巴喷丁是一种新一代抗癫痫药物，可提高大脑γ-氨基丁酸（GABA）水平。我们报告了一项为期三个月的随机双盲安慰剂对照研究结果，该研究旨在探讨加巴喷丁对符合国际头痛协会（IHS）标准的偏头痛患者的预防作用。
我们对63例有或无先兆的偏头痛患者进行了治疗。患者在家中使用对症药物治疗发作，并在日记中记录临床评估情况。在停用任何其他预防性治疗8周后，所有患者均接受1200毫克/天的加巴喷丁治疗；这是我们的治疗方案：第1至3天为400毫克/天，第4至6天为800毫克/天，第7天起为1200毫克/天。
无患者退出研究，加巴喷丁耐受性良好；不良事件（嗜睡、头晕、震颤、疲劳和共济失调）一般为短暂性，严重程度为轻至中度，仅13例（27%）患者出现。在这种情况下，治疗结束时，我们报告接受加巴喷丁治疗的30例患者偏头痛的频率和强度有显著降低。
我们的观察结果表明，加巴喷丁患者耐受性良好，且能降低两组患者的头痛频率和对症药物的使用。加巴喷丁在偏头痛的预防性治疗中显示出有效的治疗作用。
